Word

FYARRO

Status

Dead

Status Code

606

Status Date

Monday, October 23, 2023

Serial Number

88599810

Mark Type

4000

Filing Date

Friday, August 30, 2019

Published for Opposition

Tuesday, July 28, 2020

Abandoned Date

Monday, October 23, 2023

Trademark Owner History

AADi Bioscience, Inc. - Owner At Publication

Classifications

5 Pharmaceutical preparations for the treatment and prevention of cardiovascular disease, epilepsy, mitochondrial disease, central nervous system disease, infectious disease, and acute respiratory disease; vaccine preparations; pharmaceutical preparations, namely, a drug formulation comprising nanoparticles of sirolimus and albumin for use in angiology, cardiology, endocrinology, gastroenterology, geriatrics, hematology, hepatology, nephrology, neurology, pulmonology, pneumology, respirology, rheumatology, anesthesiology, urology, dermatology, gynecology, ophthalmology, infectiology, and psychiatry; pharmaceutical preparations, namely, a drug formulation comprising nanoparticles of sirolimus and albumin for use in in pediatric, geriatric, emergency, family, and psychiatry; pharmaceutical preparations for the treatment of infectious and hereditary diseases

42 Medical and pharmaceutical research services; pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; medical and scientific research, namely, conducting clinical trials for others; laboratory research services relating to pharmaceuticals; scientific and technological services, namely, research and design services in the field of process development, validation, qualification, and manufacturing of pharmaceuticals and biopharmaceuticals; scientific and technological services consultation services in the field of development, manufacturing and testing of pharmaceuticals and biopharmaceuticals; providing product research and development in the pharmaceutical field for purposes of process development, validation, qualification, and manufacturing of pharmaceuticals and biopharmaceuticals; scientific and technological consultation services in the field of pharmaceutical research and pharmacology; custom development of pharmaceutical, biopharmaceutical and chemical products; providing evaluation testing for pharmaceutical, biopharmaceutical and chemical products, and medical devices featuring testing for safety, toxicity, content, identity, purity, configuration and function, using chemical, in vitro or in vivo assays, analyses and models; pre-clinical and non-clinical evaluation testing of pharmaceutical, biopharmaceutical and chemical products performed primarily using animals and other biological models; pharmaceutical, biopharmaceutical, and chemical research and development for others; pharmaceutical research in the fields of angiology, cardiology, endocrinology, gastroenterology, geriatrics, hematology, hepatology, nephrology, neurology, oncology, pulmonology, pneumology, respirology, rheumatology, anesthesiology, urology, dermatology, gynecology, ophthalmology, infectiology, and psychiatry; pharmaceutical research for use in pediatric, geriatric, emergency, family, and preventative medicine; pharmaceutical research for the treatment of infectious, deficiency, hereditary, and physiological diseases

Trademark Events

Oct 23, 2023

Abandonment Notice E-Mailed - No Use Statement Filed

Oct 23, 2023

Abandonment - No Use Statement Filed

Mar 22, 2023

Notice Of Approval Of Extension Request E-Mailed

Mar 21, 2023

Sou Extension 5 Granted

Mar 17, 2023

Sou Extension 5 Filed

Mar 17, 2023

Sou Teas Extension Received

Sep 23, 2022

Notice Of Approval Of Extension Request E-Mailed

Sep 21, 2022

Sou Extension 4 Granted

Sep 21, 2022

Sou Extension 4 Filed

Sep 21, 2022

Sou Teas Extension Received

May 7, 2022

Notice Of Approval Of Extension Request E-Mailed

May 7, 2022

Corrected Noa E-Mailed

May 6, 2022

Sou Extension 3 Granted

Mar 22, 2022

Sou Extension 3 Filed

May 6, 2022

Divisional Processing Complete

Mar 21, 2022

Divisional Request Received

Apr 11, 2022

Teas Response To Office Action Received

Apr 5, 2022

Itu Office Action Issued For Divisional Request

Apr 1, 2022

Case Assigned To Intent To Use Paralegal

Mar 21, 2022

Teas Request To Divide Received

Mar 21, 2022

Sou Teas Extension Received

Sep 22, 2021

Notice Of Approval Of Extension Request E-Mailed

Sep 20, 2021

Sou Extension 2 Granted

Sep 20, 2021

Sou Extension 2 Filed

Sep 20, 2021

Sou Teas Extension Received

Feb 25, 2021

Notice Of Approval Of Extension Request E-Mailed

Feb 23, 2021

Sou Extension 1 Granted

Feb 23, 2021

Sou Extension 1 Filed

Feb 23, 2021

Sou Teas Extension Received

Sep 22, 2020

Noa E-Mailed - Sou Required From Applicant

Jul 28, 2020

Official Gazette Publication Confirmation E-Mailed

Jul 28, 2020

Published For Opposition

Jul 8, 2020

Notification Of Notice Of Publication E-Mailed

Jun 24, 2020

Approved For Pub - Principal Register

Jun 24, 2020

Teas/Email Correspondence Entered

Jun 24, 2020

Correspondence Received In Law Office

Jun 16, 2020

Assigned To Lie

Jun 8, 2020

Teas Response To Office Action Received

Dec 11, 2019

Notification Of Non-Final Action E-Mailed

Dec 11, 2019

Non-Final Action E-Mailed

Dec 11, 2019

Non-Final Action Written

Dec 4, 2019

Assigned To Examiner

Sep 12, 2019

New Application Office Supplied Data Entered

Sep 3, 2019

New Application Entered